Revance Reports Fourth Quarter and Full Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street futures fall as oil, Treasury yields rise on Iran tensions
- Oil prices fall after hitting over one-month high; traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- Berkshire’s Abel says data centers are energy opportunity
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Revance Therapeutics (RVNC) Reports In-Line Q4 EPS, Revenues Beat
February 22, 2021 4:41 PM ESTRevance Therapeutics (NASDAQ: RVNC) reported Q4 EPS of ($1.24), in-line with the analyst estimate of ($1.24). Revenue for the quarter came in at $11.13 million versus the consensus estimate of $8.78 million.
Fourth quarter and full year 2020 total product and service revenue of $10.2 million and $13.3 million, respectivelyFirst full quarter of RHA® Collection of dermal fillers revenue of $10.0 millionExited 2020 with over $200 million in annualized HintMD processing volumeCash, cash equivalents and short-term investments balance of $436.5 million at... More